

Thermo Fisher acquires PharmaFluidics to extend capabilities in column performance

02 November 2021 | News

Adds patterned microchip-based technology to liquid chromatography portfolio

Thermo Fisher Scientific has announced its acquisition of Belgium-based PharmaFluidics, the developer of the μ PAC range of micro-chip-based chromatography columns.

The μ PAC portfolio of columns enhance liquid chromatography (LC) performance in biomarker, proteomics and drug research and development applications, helping biotechnology and pharmaceutical companies uncover new insights and advance scientific discovery.

Through an innovative approach, separation performance and sensitivity are improved with the μ PAC chromatography columns, allowing for the identification of substantially more compounds in complex biological samples.

The μ PAC portfolio acquisition complements Thermo Fisher's existing chromatography solutions to deliver extended analytical capabilities to researchers.

"LC is a key analytical technique across numerous applications, and its accuracy, reproducibility and robustness is critical to the delivery of meaningful results," said Kent Davidson, vice president and general manager, high performance chromatography solutions, chromatography and mass spectrometry, Thermo Fisher Scientific